A new index of priority symptoms in advanced ovarian cancer

详细信息    查看全文

• 作者：Sally E. Jensen^a ; ^{sjensen@northshore.org} ; Sarah K. Rosenbloom^b ; ^c ; Jennifer L. Beaumont^b ; Amy Abernethy^d ; Paul B. Jacobsen^e ; Karen Syrjala^f ; David Cella^b ; ^c
• 关键词：Quality of life ; Symptom Index ; Ovarian Cancer
• 刊名：Gynecologic Oncology
• 出版年：2011
• 出版时间：February 2011
• 年：2011
• 卷：120
• 期：2
• 页码：214-219
• 全文大小：183 K

文摘

Objective.

This study sought to develop and examine preliminary validity of the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18), a new ovarian cancer-specific symptom index comprised of symptoms rated as highest priority by both oncology clinical experts and women with advanced ovarian cancer.

Methods.

Fifty-one women with advanced ovarian cancer rated the importance of 30 symptoms associated with advanced ovarian cancer. Ten gynecologic oncologists then rated symptoms according to whether they were predominantly disease- or treatment-related. Patient priorities were then reconciled with previously-published clinician priorities for symptom measurement in ovarian cancer. This produced the NFOSI-18. Participants also completed measures of quality of life and performance status to examine preliminary validity of the NFOSI-18.

Results.

An 18-item symptom index for advanced ovarian cancer was developed, including three subscales: disease-related symptoms, treatment-related symptoms, and general function/well-being. Lower NFOSI-18 scores indicate greater high-priority symptom burden. Preliminary reliability suggests good internal consistency (α = 0.80). The NFOSI-18 and its subscales were significantly positively associated with quality of life validity criteria. Scores on the NFOSI-18 differed significantly by performance status, with poor performance status associated with lower NFOSI-18 scores.

Conclusions.

The NFOSI-18 shows preliminary evidence for reliability and validity as a brief assessment of the most important symptoms associated with treatment for advanced ovarian cancer.